Generic Invega Hafyera Availability
Last updated on May 7, 2025.
See also: Generic Invega, Generic Invega Sustenna, Generic Invega Trinza
Invega Hafyera is a brand name of paliperidone, approved by the FDA in the following formulation(s):
INVEGA HAFYERA (paliperidone palmitate - suspension, extended release;intramuscular)
-
Manufacturer: JANSSEN PHARMS
Approval date: August 30, 2021
Strength(s): 1.092GM/3.5ML (312MG/ML) [RLD], 1.560GM/5ML (312MG/ML) [RLD]
Is there a generic version of Invega Hafyera available?
No. There is currently no therapeutically equivalent version of Invega Hafyera available in the United States.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Invega Hafyera. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: Generic Drug FAQ.
Related patents
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
-
Dosing regimens associated with extended release paliperidone injectable formulations
Patent 11,304,951
Issued: April 19, 2022
Inventor(s): Gopal; Srihari et al.
Assignee(s): Janssen Pharmaceutica NV (Beerse, BE)The present invention provides a method of treating patients with long acting injectable paliperidone palmitate formulations.
Patent expiration dates:
- May 7, 2041✓
- May 7, 2041
-
Dosing regimens associated with extended release paliperidone injectable formulations
Patent 11,324,751
Issued: May 10, 2022
Inventor(s): Gopal; Srihari et al.
Assignee(s): Janssen Pharmaceutica NV (Beerse, BE)The present invention provides a method of treating patients with long acting injectable paliperidone palmitate formulations.
Patent expiration dates:
- May 7, 2041✓
- May 7, 2041
-
Methods for ensuring resuspension of paliperidone palmitate formulations
Patent 11,666,697
Issued: June 6, 2023
Inventor(s): D'Hoore; Peter et al.
Assignee(s): Janssen Pharmaceutica NV (Beerse, BE)Provided are methods for improving resuspendability of a paliperidone palmitate extended-release injectable suspension within a syringe, for reducing a force required for injection of a paliperidone palmitate extended-release injectable suspension, or for reducing the likelihood of incomplete injection of a paliperidone palmitate extended-release injectable suspension comprising maintaining the syringe in a desired orientation during shipping of the syringe that varies from the orientation of the syringe during pre-shipping storage. Also provided are populations of syringes that respectively contain paliperidone palmitate extended release injectable suspension, wherein each of the syringes have been shipped to a destination, and the syringes were each maintained in a desired orientation during shipping of the syringe that varies from the orientation of the syringe during pre-shipping storage. The present disclosure also provides pharmaceutical products comprising a paliperidone palmitate extended-release injectable suspension within a syringe for administration to a patient suffering from schizophrenia, wherein the syringe has undergone pre-shipping storage and has been shipped, and wherein the syringe has been maintained in an orientation during the shipping that varies from the orientation of the syringe during pre-shipping storage.
Patent expiration dates:
- November 24, 2041✓
- November 24, 2041
-
Dosing regimens associated with extended release paliperidone injectable formulations
Patent 12,208,100
Issued: January 28, 2025
Inventor(s): Gopal; Srihari et al.
Assignee(s): Janssen Pharmaceutica NV (Beerse, BE)The present invention provides a method of treating patients with long acting injectable paliperidone palmitate formulations.
Patent expiration dates:
- May 7, 2041✓
- May 7, 2041✓
- May 7, 2041
More about Invega Hafyera (paliperidone)
- Check interactions
- Compare alternatives
- Pricing & coupons
- Reviews (1)
- Drug images
- Side effects
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: atypical antipsychotics
- Breastfeeding
- En español
Patient resources
Other brands
Invega, Invega Sustenna, Invega Trinza, Erzofri
Professional resources
Other brands
Invega, Invega Sustenna, Invega Trinza, Erzofri
Related treatment guides
Glossary
| Term | Definition |
|---|---|
| Drug Patent | A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation. |
| Drug Exclusivity | Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant. |
| RLD | A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
